Please use this identifier to cite or link to this item:
|Title:||All-trans retinoic acid in the treatment of acute promyelocytic leukaemia.|
|Authors:||White, K L;Wiley, J S;Frost, T;McKendrick, J J;Hermann, R P;Seldon, M;Enno, A;Bell, R;Bunce, I;Taylor, K|
|Affiliation:||Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Vic., Australia.|
|Citation:||Australian and New Zealand Journal of Medicine; 22(5): 449-54|
|Abstract:||All-trans-retinoic acid (ATRA) is known to induce differentiation of promyelocytes in vitro and also to induce remission of acute promyelocytic leukaemia in vivo. We treated 11 patients with poor prognosis acute promyelocytic leukaemia (APL) with ATRA and obtained seven complete and one partial remission. Remissions took one to three months to achieve and were associated with adverse effects including dry skin and bone pain. In eight patients the white cell count rose above 20 x 10(9)/L within the first ten days of retinoic acid treatment and this was associated with the development of pulmonary leukostasis in three patients which was fatal in one. Another two patients died of intracranial haemorrhage also within the first ten days. ATRA is a promising new agent in the induction therapy of this particular category of acute leukaemia.|
|Internal ID Number:||1445034|
Cell Differentiation.drug effects
Leukemia, Promyelocytic, Acute.blood.drug therapy.pathology
Tretinoin.adverse effects.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.